The share prices of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) is down by 5.72 percent and currently trading at $9.65 per share . The shares of the company is trading with wide intraday fluctuations in the range of $9.34 to $9.92 per during the day. The shares Raptor Pharmaceutical Corp. (NASDAQ:RPTP) has a market capitalization of $534.64 million. The stock opened at $9.88 per share. The share price does not make a change in the 52 week low value $4.35 per share and 52 week high value $10.47 per share.
Raptor Pharmaceutical Corp. (NASDAQ:RPTP) is focusing product portfolio that considering the two candidates in-licensed, getting product candidates and drug targeting platforms. This company is formerly known as Torrey Pines Therapeutics. In early This Company is development-stage Company. In clinical development it has three programs through its pipelines. Clinical-stage product partners have three candidates for its business development and preclinical product has four candidates for developing out of three was based on drug-targeting platforms on August 2010. No revenues for the company on August 2010. A reverse merger was finished by the company, ECP Acquisition, and subsidiaries and they joined with RPC for its business.
Raptor Pharmaceutical Corp. (NASDAQ:RPTP) said that PROCYSBI delayed-release capsules was granted by FDA for orphan drug exclusivity and patients age six and older for managing nephropathic cystinosis. This decision was resulted based on the cooperative and productive process with FDA. PROCYSBI was called as Raptor Cares at 1-855-888-4004 by the physicians. Through education and support Raptor Cares gave services to help patients. The company had an institutional investor’s shareholdings as 35 percent. Raptor Pharmaceutical Corp. (NASDAQ:RPTP) has been having a trading volume of 3.90 million and an average volume of 457,082 per day on Wednesday. The company presently holds 55.43 million shares outstanding in the market.
